WO2001047492A1 - Improved pharmaceutical compositions for poorly soluble drugs - Google Patents

Improved pharmaceutical compositions for poorly soluble drugs Download PDF

Info

Publication number
WO2001047492A1
WO2001047492A1 PCT/AU2000/001592 AU0001592W WO0147492A1 WO 2001047492 A1 WO2001047492 A1 WO 2001047492A1 AU 0001592 W AU0001592 W AU 0001592W WO 0147492 A1 WO0147492 A1 WO 0147492A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
drug
composition according
suspension
polymer
Prior art date
Application number
PCT/AU2000/001592
Other languages
French (fr)
Inventor
David Hayes
Angelo Mario Morella
Original Assignee
F H Faulding & Co Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25646230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001047492(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AUPQ4854A external-priority patent/AUPQ485499A0/en
Priority claimed from AUPQ7450A external-priority patent/AUPQ745000A0/en
Application filed by F H Faulding & Co Limited filed Critical F H Faulding & Co Limited
Priority to EP00986890A priority Critical patent/EP1239831B1/en
Priority to JP2001548087A priority patent/JP5159012B2/en
Priority to ES00986890T priority patent/ES2398643T3/en
Priority to CA2396380A priority patent/CA2396380C/en
Priority to AU23318/01A priority patent/AU2331801A/en
Publication of WO2001047492A1 publication Critical patent/WO2001047492A1/en
Priority to US10/175,883 priority patent/US20030086976A1/en
Priority to US10/461,503 priority patent/US6881745B2/en
Priority to US11/763,578 priority patent/US8771739B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Definitions

  • the present invention relates to improved pharmaceutical compositions of drugs that are practically insoluble in aqueous media.
  • the present invention also relates to a process for preparing the compositions.
  • the present invention relates to improved dosage forms for the administration of the compositions.
  • Drugs that are totally water-insoluble, or are at least poorly water-soluble, are usually characterised by low absorption and poor bioavailability, and present special difficulties when formulating dosage forms therefor. For the purposes of this specification, such drugs will be referred to as being "practically insoluble".
  • the dosage forms in both applications are said to have good bioavailability in a form suitable for oral administration, and are both designed for dissolution in the stomach.
  • the present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food.
  • the composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.
  • the present invention also provides a pharmaceutical composition of a practically insoluble drug, the composition having an AUC under fed conditions that is 80% to 125% of the composition's AUC under fasted conditions.
  • the composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.
  • the present invention provides a pharmaceutical composition of a practically insoluble drug, wherein in vitro the composition forms a suspension.
  • the composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups.
  • the pharmaceutical composition may include other components within it, such as disintegrants, diluents, fillers and the like.
  • the term "practically insoluble” as used herein applies to drugs that are essentially totally water-insoluble or are at least poorly water-soluble. More specifically, the term is applied to any drug that has a dose (mg) to aqueous solubility (mg/ml) ratio greater than 100ml, where the drug solubility is that of the neutral (for example, free base or free acid) form in unbuffered water. This meaning is to include, but is not to be limited to, drugs that have essentially no aqueous solubility (less than 1.0 mg/ml).
  • drug will be widely understood and denotes a compound having beneficial prophylactic and/or therapeutic properties when administered to, for example, humans. Further, the term “drug per se” is used throughout this specification for the purposes of comparison, and means the drug when in an aqueous solution/suspension without the addition of any excipients.
  • solid dispersion in general means a system in solid state comprising at least two components, wherein one component is dispersed more or less evenly throughout the other component or components.
  • solid dispersions are the dispersion of one or more active ingredients in an inert carrier or matrix at solid state, prepared by the melting, solvent, or melting- solvent methods.
  • n vivo in general means in the living body of a plant or animal, whereas the term “in vitro” generally means outside the body and in an artificial environment.
  • the pharmaceutical composition is such that, upon administration, a suspension is formed in vivo.
  • the suspension is a homogeneous dispersion of particles (containing the drug), the particles at least being of a size where, in vitro, they diffract light such that the suspension presents as a cloudy suspension.
  • the particles in the cloudy suspension in vitro will generally be particles of a size greater than about 1 nm but less than about 10 micrometre.
  • In vitro dissolution testing of a pharmaceutical composition according to this form of the present invention reveals that particles in this size range are present when tested at a pH in the range of 5.5 to 7.5.
  • in vitro dissolution testing of a pharmaceutical composition according to this form of the present invention again reveals that particles in this size range are present when subsequently tested at a pH in the range of 5.5 to 7.5. This pre-treatment may be conducted to simulate in vivo conditions.
  • nanoparticulate form such as in the range of 1 nm to 450 nm
  • microparticulate form such as in the range of 0.45 micrometre to 10 micrometre.
  • the presence of such nanoparticles in vivo may be determined by testing for them in vitro, such as by passing the cloudy suspension through a 450 nm filter and having the suspension remain cloudy.
  • Such nanoparticles are preferably present regardless of whether the acidic pre-treatment step described above is utilised in the testing procedure.
  • the present invention additionally provides a pharmaceutical composition of a practically insoluble drug, wherein the composition forms a suspension in vitro at a pH in the range of 5.5 to 7.5, the suspension having particles in the size range of 1 nm to 10 micrometre, with or without a pre- treatment at acidic pH.
  • the suspension has at least a portion of its particles in the size range of 1 nm to 450 nm in vitro at a pH in the range of 5.5 to 7.5, again with or without a pre-treatment at acidic pH.
  • the pharmaceutical composition may therefore provide for acceptable absorption of the practically insoluble drug (where acceptable absorption is indicated by the extent of the absorption being greater than that of the crystallised form of the drug per se), in the intestines where the pH is expected to be in the range of 5.5 to 7.5.
  • the pharmaceutical composition may be administered with food or without food.
  • This is beneficial as many practically insoluble drugs are unable to be formulated in a manner that allows administration without food, particularly those typically formulated as solid dosage forms. This makes administration of these dosage forms cumbersome and quite inflexible for the patient.
  • the pharmaceutical composition of the present invention is preferably bioequivalent when administered under fed conditions compared to administration under fasted conditions.
  • the AUC for a composition administered under fed conditions is preferably within the range of 80 to 125% of the AUC under fasted conditions, when considering the 90% confidence interval for the ratio of the fed value to the fasted value (using natural log transformed data).
  • any practically insoluble drug may be beneficially used in the pharmaceutical composition of the present invention.
  • many drugs whether considered practically insoluble or not
  • versions crystalline forms, polymorphs, etc
  • drugs developed in the future that are also considered to be practically insoluble, are also to be included within the scope of the present invention.
  • azole antifungal drugs such as itraconazole and saperconazole
  • similar benefits will be available for other classes of drugs such as anti-hypertensives, immunosuppressants, anti- inflammatories, diuretics, antiepileptics, cholesterol lowering drugs, hormonals, hypoglycemics, antiviral drugs, nasal decongestants, antimicrobials, anti- arrthrytics, analgesics, anti-cancer drugs, anti-parasitics, proteins, peptides, CNS stimulants, CNS depressants, 5 HT inhibitors, anti-schizophrenics, anti- Alzheimer drugs, anti-psoriatics, steroidals, oligonucleotides, anti-ulcer drugs, proton pump inhibitors, anti-asthmatics, thrombolyitics and vitamins.
  • the polymers useful for forming the solid dispersion of the pharmaceutical composition of the present invention are those having acidic functional groups.
  • such polymers will be polycarboxylic acids.
  • Such polycarboxylic acids may be any polycarboxylic acid which, when in a solid dispersion with a practically insoluble drug, results in the formation of the abovementioned suspension, ideally in the preferred pH ranges, and preferably to provide acceptable absorption in the intestines.
  • Such polymers may be one or more of the group comprising hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate (PVAP), hydroxypropylmethylcellulose acetate succinate (HPMCAS), alginate, carbomer, carboxymetr-yl cellulose, methacrylic acid copolymer, shellac, cellulose acetate phthal te (CAP), starch glycolate, polacrylin, methyl cellulose acetate phthalate, hydroxypropylcellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate and cellulose acetate trimellitate, and includes the various grades of each polymer such as HPMCAS-LF, HPMCAS-MF and HPMCAS-HG.
  • PVAP polyvinyl acetate phthalate
  • HPMCAS hydroxypropylmethylcellulose acetate succinate
  • alginate carbomer
  • carboxymetr-yl cellulose methacrylic acid copolymer
  • the polymer is a polycarboxylic acid such as a hydroxypropyl methylcellulose phthalate such as that available from Shin-Etsu Chemical Industry Co Ltd as HP-50, HP-55 or HP- 55S.
  • a polycarboxylic acid such as a hydroxypropyl methylcellulose phthalate such as that available from Shin-Etsu Chemical Industry Co Ltd as HP-50, HP-55 or HP- 55S.
  • an aqueous based enteric polymer such as the dispersion Eudragit L30D, or enteric polymers dissolved in water with the addition of ammonia or alkaline agents, may be useful.
  • the ratio of drug to polymer may be in the range of from 3:1 to 1 :20. However, ratios in the narrower range of 3:1 to 1 :5 are preferred. An even more preferred range is 1 :1 to 1 :3, with the most preferred ratio being about 1 :1.5 (or 2:3).
  • the solid dispersion of the composition of the present invention is preferably formed by spray drying techniques, although it will be understood that suitable solid dispersions may be formed by a skilled addressee utilising other conventional techniques, such as co-grinding, melt extrusion, freeze drying, rotary evaporation or any solvent removal process.
  • the solid dispersion is formed by dispersing or dissolving the drug and the polymer in a suitable solvent, and subsequently spray drying to form the solid dispersion in the form of a powder.
  • suitable solvents or dispersion media include methylene chloride, chloroform, ethanol, methanol, propan-2-ol, ethylacetate, acetone, water or mixtures thereof.
  • Other excipients may then be blended into the powder (with or without milling or grinding) to form a composition suitable for use in dosage forms such as tablets and capsules.
  • the present invention therefore also provides a process for preparing a pharmaceutical composition of a practically insoluble drug, the process including dispersing in a solvent the drug and a polymer having acidic functional groups, and spray drying the dispersion to form a solid dispersion.
  • the present invention may thus provide a process for preparing a pharmaceutical composition of a practically insoluble drug, where the process includes the steps of:
  • the present invention may provide a process for preparing a pharmaceutical composition of a practically insoluble drug, where the process includes the steps of:
  • composition of the present invention may be formulated into pharmaceutical dosage forms comprising a therapeutically effective amount of the composition.
  • pharmaceutical dosage forms for oral administration such as tablets and capsules
  • the composition of the present invention can also be used to prepare other pharmaceutical dosage forms, such as for rectal, vaginal, ocular or buccal administration, or the like.
  • the solid dispersions of the composition of the invention may be spray coated (or the like) onto cores to produce particles suitable for use in any of these dosage forms.
  • dosage forms may include a range of traditional excipients such as disintegrants, diluents, fillers, lubricants, glidants, colourants and flavours.
  • suitable disintegrants may be those that have a large coefficient of expansion, and examples may include crosslinked polymers such as crospovidone (crosslinked polyvinylpyrrolidone), croscarmellose (crosslinked sodium carboxymethylcellulose), and sodium starch glycolate.
  • crosslinked polymers such as crospovidone (crosslinked polyvinylpyrrolidone), croscarmellose (crosslinked sodium carboxymethylcellulose), and sodium starch glycolate.
  • an inert substance such as a diluent or a filler.
  • a diluent or a filler a variety of materials may be used as diluents or fillers, and examples may be sucrose, dextrose, mannitol, sorbitol, starch, micro-crystalline cellulose, and others known in the art, and mixtures thereof.
  • Lubricants and glidants may be employed in the manufacture of certain dosage forms, and will usually be employed when producing tablets.
  • examples of lubricants and glidants are hydrogenated vegetable oils, magnesium stearate, stearic acid, sodium lauryl sulfate, magnesium lauryl sulfate, colloidal silica, talc, mixtures thereof, and others known in the art.
  • a preferred lubricant is magnesium stearate, or mixtures of magnesium stearate with colloidal silica.
  • Excipients such as colouring agents and pigments may also be added to dosage forms in accordance with the present invention, and suitable colouring agents and pigments may include titanium dioxide and dyes suitable for food.
  • Flavours may be chosen from synthetic flavour oils and flavouring aromatics or natural oils, extracts from plants, leaves, flowers, fruits and so forth and combinations thereof. These may include cinnamon oil, oil of wintergreen, peppermint oils, bay oil, anise oil, eucalyptus, thyme oil. Also useful as flavours are vanilla, citrus oil, including lemon, orange, grape, lime and grapefruit, and fruit essences including apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so forth.
  • the parameters that are commonly used in the art to describe the in vivo performance of a formulation (or the bioavailability) are C ma ⁇ (the maximum concentration of the active in the blood) and, as mentioned previously, AUC (area under the curve - a measure of the total amount of drug absorbed by the patient).
  • C ma ⁇ the maximum concentration of the active in the blood
  • AUC area under the curve - a measure of the total amount of drug absorbed by the patient.
  • the 90% confidence interval for the ratio of the test to reference product (using natural log-transformed data) for C max and AUC are within the range of 80 to 125%.
  • compositions in accordance with the present invention it has been found that drugs previously considered to present bioavailability problems may be presented in dosage forms with superior bioavailability.
  • the inventive compositions have produced formulations that are not considered bioequivalents to, but have at least twice the bioavailability of, a commercially available itraconazole product (Sporanox TM).
  • SporanoxTM a commercially available itraconazole product
  • the inventive compositions have produced formulations tiat have reduced food effect and thus need not be administered with food (unlike SporanoxTM).
  • the present invention also provides a pharmaceutical composition in the form of a solid dispersion of a polymer with acidic functional groups (preferably a polycarboxylic acid such as a hydroxypropyl methylcellulose phthalate) and an azole antifungal drug (such as itraconazole), wherein in vitro the composition forms a suspension.
  • a pharmaceutical composition in the form of a solid dispersion of a polymer with acidic functional groups (preferably a polycarboxylic acid such as a hydroxypropyl methylcellulose phthalate) and an azole antifungal drug (such as itraconazole), wherein in vitro the composition forms a suspension.
  • the composition upon administration forms a suspension at a pH in the range of 4.0 to 8.0, but more preferably in the range 5.5 to 7.5, and may provide acceptable absorption in the intestines.
  • the present invention further provides a pharmaceutical composition in the form of a solid dispersion of a hydroxypropyl methylcellulose phthalate and a practically insoluble drug, wherein the composition forms a suspension in vitro in the pH range of 4.0 to 8.0 (preferably 5.5 to 7.5) and preferably provides acceptable absorption in the intestines.
  • the present invention is a pharmaceutical composition in the form of a solid dispersion of itraconazole that provides a mean C max of at least 100 ng/ml when a dose of 100 mg of itraconazole is given in the fasted state.
  • a more preferred form is such a formulation of itraconazole that provides a mean C ma ⁇ of 150 to 250 ng/ml, when a dose of 100 mg of itraconazole is given in the fasted state.
  • a further form of the present invention is a pharmaceutical composition in the form of a solid dispersion of itraconazole that provides a mean AUC at least 800 ng.h/ml when a dosage of 100 mg of itraconazole is given in the fasted state.
  • a more preferred form is such a solid dispersion of itraconazole that provides a mean AUC of 1300 to 2300 ng.h/ml, when a dose of 100 mg of itraconazole is given in the fasted state.
  • the bioavailability of the drug as compared to the drug per se is improved by at least 50% and more preferably 100%, in terms of AUC.
  • a solution was prepared by dispersing HP-50 (60g) in methylene chloride (1200 g) and then adding itraconazole (40 g) and stirring to form a pale brown solution. This solution was then spray dried to form a powder.
  • a portion (38.96 g) of this spray dried powder was then blended with sodium starch glycolate (14.87 g) and colloidal silicon dioxide (Aerosil 200)(0.75 g) in a mortar and pestle for 5 minutes.
  • Magnesium stearate (1. 1 g) was added to the blend from the mortar and the mixture tumble blended until uniform.
  • This powder blend was then filled into size 0 gelatin capsules by hand. Each capsule was filled with 364 to 378 mg of powder, containing nominally 98 to 102 mg of itraconazole.
  • capsules were tested in a standard USP type II dissolution bath (paddle method).
  • a capsule was weighted with stainless steel wire and then dropped into 900 ml of dissolution media consisting of 0.05 M phosphate buffer solution adjusted to pH 6.0.
  • Samples of this media were extracted at appropriate time intervals through a 10 micrometre filter and the content of itraconazole in the sample assayed using a HPLC method. Both the media in the dissolution bath and the extracted, filtered samples were cloudy in appearance.
  • This test was also performed using 900 ml of hydrochloric acid acidic media (pH 1.2, 0.06 M HCI). In this case both the media and the samples were clear.
  • a solution was prepared by dispersing HP-50 (420 g) in methylene chloride (8400 g) and then adding itraconazole (280 g) and stirring to form a pale brown solution. This solution was then spray dried to form a powder.
  • This powder blend was then filled into size 0 gelatin capsules by hand. Each capsule was filled with 345 to 359 mg of powder, containing nominally 98 to 102 mg of itraconazole.
  • test capsules were utilised in a pharmacokinetic study. 8 male volunteers were dosed with one 100 mg capsule after an overnight (10 hour) fast. The capsules were dosed with 240 ml water. At appropriate time intervals blood samples were taken from the subjects and the concentration of itraconazole in the plasma determined. The study was performed in a randomised 2 way crossover fashion with subjects receiving 100 mg itraconazole as a marketed capsule (SporanoxTM) or as the test formulation described in example 2 above. The alternate dose was taken after a 2 week washout period.
  • a plot of the mean blood levels measured is as follows:
  • the itraconazole formulation of this invention would have a later T ma ⁇ (time to maximum blood concentration of active) than SporanoxTM, due to the use of an enteric polymer, which should not have solublised until after passing through the stomach. This is in comparison to the water-soluble polymers used in SporanoxTM that would solublise in the stomach.
  • the T max of the formulation of the present invention is at least similar to the T max of SporanoxTM, if not shorter than it. Together with the greatly increased C max , this result was surprising.
  • Test capsules from Example 2 containing 100 mg of itraconazole were also utilised in a pharmacokinetic study under fed conditions, primarily for comparison with the pharmacokinetic results of Example 2 to determine whether there was any food effect.
  • the study was again conducted as a single dose, crossover study in 8 health male adult subjects, but under fed conditions.
  • the subjects commenced eating a standard high fat breakfast 20 minutes prior to dose administration, having fasted for at least 10 hours prior to that.
  • a plot of the mean blood levels from the fasted study of example 2 (Fasted Study CM4799) and the fed study of Example 3 (Fed Study CM6000) is as follows:
  • the example formulation produces plasma profiles considered bioequivalent in terms of AUC under fasting and fed conditions, due to the AUC under fed conditions being about 102% of the AUC under fasted conditions, which is well within the range of 80 to 120%. This is an indication that the total amount of drug absorbed over time is essentially equivalent under fed and fasted conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.

Description

IMPROVED PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS
Field of the Invention
The present invention relates to improved pharmaceutical compositions of drugs that are practically insoluble in aqueous media. The present invention also relates to a process for preparing the compositions. Furthermore, the present invention relates to improved dosage forms for the administration of the compositions.
Background of the Invention
Drugs that are totally water-insoluble, or are at least poorly water-soluble, are usually characterised by low absorption and poor bioavailability, and present special difficulties when formulating dosage forms therefor. For the purposes of this specification, such drugs will be referred to as being "practically insoluble".
Indeed, it has been reported that the bioavailability of many practically insoluble drugs is limited by their dissolution rates and solubility, which in turn are understood to be controlled by the surface area that they present for dissolution. As such, attempts to improve the bioavailability of these practically insoluble drugs have often focussed on particle size reduction.
Examples of attempts to improve the bioavailability of such drugs are illustrated in international patent applications PCT/EP93/02327 and PCT/EP98/01773 both to Janssen Pharmaceutica N.V. These applications both relate to dosage forms of azole antifungals, such as itraconazole and saperconazole, which are said to be only very sparingly soluble in water, and both describe the incorporation of the drug with water-soluble polymers and the subsequent coating of the mixture on small beads. In PCT/EP93/02327 the beads are 600 to 700 micrometre in diameter, whereas in PCT/EP98/01773 the beads are 250 to 355 micrometre in diameter.
The dosage forms in both applications are said to have good bioavailability in a form suitable for oral administration, and are both designed for dissolution in the stomach.
Janssen adopted a different approach in international patent application PCT/EP97/02507, again for azole antifungals such as itraconazole and saperconazole. In this patent application, the proposed solution to the bioavailability problem is to form a solid dispersion of the practically insoluble drug and a water soluble polymer, with ratios of drug to polymer that aim to dissolve the drug to ensure that the required bioavailability is obtained.
Another approach is reported in the article "Oral Absorption Improvement of Poorly Soluble Drug Using Solid Dispersion Technique" by T. Kai et al (Chem. Pharm. Bull. 44(3) 568-571 (1996)) in relation to another antifungal agent, again said to be of low solubility and exhibiting poor oral absorption characteristics. In this article, a solid dispersion of the drug is formed with an enteric polymer and the dissolution characteristics of the solid dispersion are tested in suitable media at pH 1.2 and pH 6.8, with a view to determining the dissolution state of the drug. The article verifies that the drug at pH 6.8 is fully dissolved (supersaturated) and is thus bioavailable, whereas at pH 1.2 the enteric polymers had not dissolved, preventing dissolution of the drug. The article thus promotes as important the supersaturation (complete dissolution) of the drug to ensure adequate bioavailability.
A final attempt to be illustrated is that of European patent application 98305960.1 to Pfizer Products Inc. This application is again aimed at improving the bioavailability of low-solubility drugs such as glycogen phosphorylase inhibitors, 5-lipoxygenase inhibitors, corticotropic releasing hormone inhibitors and antipsychotics. The Pfizer patent application suggests the use of a solid dispersion of an enteric polymer (namely, hydroxypropylmethylcellulose acetate succinate [HPMCAS]) with the low-solubility drug, again to produce a supersaturated solution in vivo to ensure adequate bioavailability. Indeed, this application specifically aims to produce a supersaturated solution of the drug in order to keep the drug dissolved for as long as possible after administration.
Further in relation to practically insoluble drugs, it has been reported that many such drugs are formulated into dosage forms that should only be administered with food. For example, a commercially available itraconazole dosage form (Sporanox™) is only prescribed for use with food because of relatively poor bioavailability results when administered under fasted conditions.
It is an aim of the present invention to provide a pharmaceutical composition with improved bioavailability for drugs that are considered to be practically insoluble.
However, before turning to discuss the invention, it should be appreciated that the above discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia or elsewhere before the priority date of each claim of this application.
Summary of the Invention
The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. In this form of the invention, the composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.
The present invention also provides a pharmaceutical composition of a practically insoluble drug, the composition having an AUC under fed conditions that is 80% to 125% of the composition's AUC under fasted conditions. In this form of the invention, the composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.
Further, the present invention provides a pharmaceutical composition of a practically insoluble drug, wherein in vitro the composition forms a suspension. In a preferred form, the composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups.
Of course, in all forms of the present invention, and as will be explained below, it will be appreciated that the pharmaceutical composition may include other components within it, such as disintegrants, diluents, fillers and the like.
Various terms that will be used throughout this specification have meanings that will be well understood by a skilled addressee. However, for ease of reference, some of these terms will now be defined.
The term "practically insoluble" as used herein applies to drugs that are essentially totally water-insoluble or are at least poorly water-soluble. More specifically, the term is applied to any drug that has a dose (mg) to aqueous solubility (mg/ml) ratio greater than 100ml, where the drug solubility is that of the neutral (for example, free base or free acid) form in unbuffered water. This meaning is to include, but is not to be limited to, drugs that have essentially no aqueous solubility (less than 1.0 mg/ml). The term "drug" will be widely understood and denotes a compound having beneficial prophylactic and/or therapeutic properties when administered to, for example, humans. Further, the term "drug per se" is used throughout this specification for the purposes of comparison, and means the drug when in an aqueous solution/suspension without the addition of any excipients.
The term "a solid dispersion" in general means a system in solid state comprising at least two components, wherein one component is dispersed more or less evenly throughout the other component or components. In particular, and with reference to a widely accepted definition from the early 1970's, "solid dispersions" are the dispersion of one or more active ingredients in an inert carrier or matrix at solid state, prepared by the melting, solvent, or melting- solvent methods.
The term "/'n vivo" in general means in the living body of a plant or animal, whereas the term "in vitro" generally means outside the body and in an artificial environment.
Reference throughout this specification will be made to the administration of a pharmaceutical composition under fed conditions or fasted conditions. It is well understood in the art that the pharmacokinetic performance of some compositions is affected by the presence or not of food in the gastro-intestinal system. Other compositions are not so affected. These references thus relate to the normally accepted administration circumstances that are referred to in the art as 'fed' or 'fasted'.
Reference will also be made to the pharmacokinetic parameter AUC. This is a widely accepted parameter determined from the graphical presentation of actual or theoretical plasma profiles (concentration vs time), and represents the area under the curve (AUC) of such a profile. General Description of the Invention
Returning now to a general description of the present invention, in one form of the invention the pharmaceutical composition is such that, upon administration, a suspension is formed in vivo. Preferably, the suspension is a homogeneous dispersion of particles (containing the drug), the particles at least being of a size where, in vitro, they diffract light such that the suspension presents as a cloudy suspension. Thus, evidence of the presence of such a cloudy suspension can be seen during in vitro dissolution testing of the solid dispersion of the inventive composition.
The particles in the cloudy suspension in vitro will generally be particles of a size greater than about 1 nm but less than about 10 micrometre. In vitro dissolution testing of a pharmaceutical composition according to this form of the present invention reveals that particles in this size range are present when tested at a pH in the range of 5.5 to 7.5. Additionally, when pretreated at acidic pH (namely, when suspended in a dissolution medium at a pH of about 1.2 for a period of about 20 minutes), in vitro dissolution testing of a pharmaceutical composition according to this form of the present invention again reveals that particles in this size range are present when subsequently tested at a pH in the range of 5.5 to 7.5. This pre-treatment may be conducted to simulate in vivo conditions.
In one form of the present invention, it may be preferred for a portion of the particles to be present in nanoparticulate form, such as in the range of 1 nm to 450 nm, and a portion to be present in microparticulate form (such as in the range of 0.45 micrometre to 10 micrometre). The presence of such nanoparticles in vivo may be determined by testing for them in vitro, such as by passing the cloudy suspension through a 450 nm filter and having the suspension remain cloudy. Such nanoparticles are preferably present regardless of whether the acidic pre-treatment step described above is utilised in the testing procedure. Therefore, the present invention additionally provides a pharmaceutical composition of a practically insoluble drug, wherein the composition forms a suspension in vitro at a pH in the range of 5.5 to 7.5, the suspension having particles in the size range of 1 nm to 10 micrometre, with or without a pre- treatment at acidic pH. Preferably, the suspension has at least a portion of its particles in the size range of 1 nm to 450 nm in vitro at a pH in the range of 5.5 to 7.5, again with or without a pre-treatment at acidic pH.
In this preferred form, the pharmaceutical composition may therefore provide for acceptable absorption of the practically insoluble drug (where acceptable absorption is indicated by the extent of the absorption being greater than that of the crystallised form of the drug per se), in the intestines where the pH is expected to be in the range of 5.5 to 7.5.
In another form of the present invention (as mentioned above), the pharmaceutical composition may be administered with food or without food. This is beneficial as many practically insoluble drugs are unable to be formulated in a manner that allows administration without food, particularly those typically formulated as solid dosage forms. This makes administration of these dosage forms cumbersome and quite inflexible for the patient. Indeed, the pharmaceutical composition of the present invention is preferably bioequivalent when administered under fed conditions compared to administration under fasted conditions. In particular, the AUC for a composition administered under fed conditions is preferably within the range of 80 to 125% of the AUC under fasted conditions, when considering the 90% confidence interval for the ratio of the fed value to the fasted value (using natural log transformed data).
Any practically insoluble drug may be beneficially used in the pharmaceutical composition of the present invention. In this respect, it should be appreciated that while the specification will here list various drugs that are typically considered to be practically insoluble, many drugs (whether considered practically insoluble or not) will have versions (crystalline forms, polymorphs, etc) that are in fact practically insoluble. Also, it is to be appreciated that drugs developed in the future that are also considered to be practically insoluble, are also to be included within the scope of the present invention.
While the specific benefits of the pharmaceutical composition of the present invention have been established by the inventors for azole antifungal drugs, such as itraconazole and saperconazole, similar benefits will be available for other classes of drugs such as anti-hypertensives, immunosuppressants, anti- inflammatories, diuretics, antiepileptics, cholesterol lowering drugs, hormonals, hypoglycemics, antiviral drugs, nasal decongestants, antimicrobials, anti- arrthrytics, analgesics, anti-cancer drugs, anti-parasitics, proteins, peptides, CNS stimulants, CNS depressants, 5 HT inhibitors, anti-schizophrenics, anti- Alzheimer drugs, anti-psoriatics, steroidals, oligonucleotides, anti-ulcer drugs, proton pump inhibitors, anti-asthmatics, thrombolyitics and vitamins.
Indeed, even though the following description will mainly describe embodiments of the invention with respect to azole antifungal drugs, it is to be appreciated that the invention is not to be so limited.
The polymers useful for forming the solid dispersion of the pharmaceutical composition of the present invention are those having acidic functional groups. In a preferred form, such polymers will be polycarboxylic acids. Such polycarboxylic acids may be any polycarboxylic acid which, when in a solid dispersion with a practically insoluble drug, results in the formation of the abovementioned suspension, ideally in the preferred pH ranges, and preferably to provide acceptable absorption in the intestines.
Such polymers may be one or more of the group comprising hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate (PVAP), hydroxypropylmethylcellulose acetate succinate (HPMCAS), alginate, carbomer, carboxymetr-yl cellulose, methacrylic acid copolymer, shellac, cellulose acetate phthal te (CAP), starch glycolate, polacrylin, methyl cellulose acetate phthalate, hydroxypropylcellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate and cellulose acetate trimellitate, and includes the various grades of each polymer such as HPMCAS-LF, HPMCAS-MF and HPMCAS-HG.
In a particularly preferred form of the present invention, the polymer is a polycarboxylic acid such as a hydroxypropyl methylcellulose phthalate such as that available from Shin-Etsu Chemical Industry Co Ltd as HP-50, HP-55 or HP- 55S. However, it is envisaged that alternatives such as the use of an aqueous based enteric polymer, such as the dispersion Eudragit L30D, or enteric polymers dissolved in water with the addition of ammonia or alkaline agents, may be useful.
In relation to amounts of drug and the polymer in the solid dispersion, the ratio of drug to polymer may be in the range of from 3:1 to 1 :20. However, ratios in the narrower range of 3:1 to 1 :5 are preferred. An even more preferred range is 1 :1 to 1 :3, with the most preferred ratio being about 1 :1.5 (or 2:3).
The solid dispersion of the composition of the present invention is preferably formed by spray drying techniques, although it will be understood that suitable solid dispersions may be formed by a skilled addressee utilising other conventional techniques, such as co-grinding, melt extrusion, freeze drying, rotary evaporation or any solvent removal process.
In the preferred spray drying technique, the solid dispersion is formed by dispersing or dissolving the drug and the polymer in a suitable solvent, and subsequently spray drying to form the solid dispersion in the form of a powder. Suitable solvents or dispersion media include methylene chloride, chloroform, ethanol, methanol, propan-2-ol, ethylacetate, acetone, water or mixtures thereof. Other excipients may then be blended into the powder (with or without milling or grinding) to form a composition suitable for use in dosage forms such as tablets and capsules.
The present invention therefore also provides a process for preparing a pharmaceutical composition of a practically insoluble drug, the process including dispersing in a solvent the drug and a polymer having acidic functional groups, and spray drying the dispersion to form a solid dispersion.
The present invention may thus provide a process for preparing a pharmaceutical composition of a practically insoluble drug, where the process includes the steps of:
(a) adding a polymer having acidic functional groups to a solvent to form a dispersion;
(b) adding the drug to the dispersion to form a suspension or solution; and
(c) spray drying the suspension or solution to form the pharmaceutical composition in the form of a solid dispersion.
Alternatively, the present invention may provide a process for preparing a pharmaceutical composition of a practically insoluble drug, where the process includes the steps of:
(a) adding the drug to a solvent to form a dispersion;
(b) adding a polymer having acidic functional groups drug to the dispersion to form a suspension or solution; and
(c) spray drying the suspension or solution to form the pharmaceutical composition in the form of a solid dispersion.
The composition of the present invention may be formulated into pharmaceutical dosage forms comprising a therapeutically effective amount of the composition. Although pharmaceutical dosage forms for oral administration, such as tablets and capsules, are envisaged, the composition of the present invention can also be used to prepare other pharmaceutical dosage forms, such as for rectal, vaginal, ocular or buccal administration, or the like. It should also be appreciated that the solid dispersions of the composition of the invention may be spray coated (or the like) onto cores to produce particles suitable for use in any of these dosage forms.
It will also be appreciated that various of these dosage forms may include a range of traditional excipients such as disintegrants, diluents, fillers, lubricants, glidants, colourants and flavours.
For example, suitable disintegrants may be those that have a large coefficient of expansion, and examples may include crosslinked polymers such as crospovidone (crosslinked polyvinylpyrrolidone), croscarmellose (crosslinked sodium carboxymethylcellulose), and sodium starch glycolate.
Also, it will be appreciated that it may be advantageous to add to a dosage form an inert substance such as a diluent or a filler. A variety of materials may be used as diluents or fillers, and examples may be sucrose, dextrose, mannitol, sorbitol, starch, micro-crystalline cellulose, and others known in the art, and mixtures thereof.
Lubricants and glidants may be employed in the manufacture of certain dosage forms, and will usually be employed when producing tablets. Examples of lubricants and glidants are hydrogenated vegetable oils, magnesium stearate, stearic acid, sodium lauryl sulfate, magnesium lauryl sulfate, colloidal silica, talc, mixtures thereof, and others known in the art. A preferred lubricant is magnesium stearate, or mixtures of magnesium stearate with colloidal silica. Excipients such as colouring agents and pigments may also be added to dosage forms in accordance with the present invention, and suitable colouring agents and pigments may include titanium dioxide and dyes suitable for food.
Flavours may be chosen from synthetic flavour oils and flavouring aromatics or natural oils, extracts from plants, leaves, flowers, fruits and so forth and combinations thereof. These may include cinnamon oil, oil of wintergreen, peppermint oils, bay oil, anise oil, eucalyptus, thyme oil. Also useful as flavours are vanilla, citrus oil, including lemon, orange, grape, lime and grapefruit, and fruit essences including apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so forth.
With reference to the pharmocokinetic performance of pharmaceutical compositions in accordance with the present invention, it will be appreciated that the parameters that are commonly used in the art to describe the in vivo performance of a formulation (or the bioavailability) are Cmaχ (the maximum concentration of the active in the blood) and, as mentioned previously, AUC (area under the curve - a measure of the total amount of drug absorbed by the patient). These are also the parameters used by regulatory agencies around the world to assess bioequivalence of different formulations. For instance, to be considered bioequivalent, the 90% confidence interval for the ratio of the test to reference product (using natural log-transformed data) for Cmax and AUC are within the range of 80 to 125%.
By utilising compositions in accordance with the present invention, it has been found that drugs previously considered to present bioavailability problems may be presented in dosage forms with superior bioavailability. For instance, and as will be described in more detail below with respect to two examples, where the drug is itraconazole the inventive compositions have produced formulations that are not considered bioequivalents to, but have at least twice the bioavailability of, a commercially available itraconazole product (Sporanox ™). Additionally, and again in comparison with Sporanox™, the inventive compositions have produced formulations tiat have reduced food effect and thus need not be administered with food (unlike Sporanox™).
Furthermore, the present invention also provides a pharmaceutical composition in the form of a solid dispersion of a polymer with acidic functional groups (preferably a polycarboxylic acid such as a hydroxypropyl methylcellulose phthalate) and an azole antifungal drug (such as itraconazole), wherein in vitro the composition forms a suspension. Preferably, the composition upon administration forms a suspension at a pH in the range of 4.0 to 8.0, but more preferably in the range 5.5 to 7.5, and may provide acceptable absorption in the intestines.
The present invention further provides a pharmaceutical composition in the form of a solid dispersion of a hydroxypropyl methylcellulose phthalate and a practically insoluble drug, wherein the composition forms a suspension in vitro in the pH range of 4.0 to 8.0 (preferably 5.5 to 7.5) and preferably provides acceptable absorption in the intestines.
Finally, in a preferred form the present invention is a pharmaceutical composition in the form of a solid dispersion of itraconazole that provides a mean Cmax of at least 100 ng/ml when a dose of 100 mg of itraconazole is given in the fasted state. A more preferred form is such a formulation of itraconazole that provides a mean Cmaχ of 150 to 250 ng/ml, when a dose of 100 mg of itraconazole is given in the fasted state.
A further form of the present invention is a pharmaceutical composition in the form of a solid dispersion of itraconazole that provides a mean AUC at least 800 ng.h/ml when a dosage of 100 mg of itraconazole is given in the fasted state. A more preferred form is such a solid dispersion of itraconazole that provides a mean AUC of 1300 to 2300 ng.h/ml, when a dose of 100 mg of itraconazole is given in the fasted state. For formulations in accordance with the present invention containing drugs other than itraconazole it is preferred that the bioavailability of the drug as compared to the drug per se is improved by at least 50% and more preferably 100%, in terms of AUC.
Description of the Preferred Embodiments
Reference will now be made to examples that embody the above general principles of the present invention. However, it is to be understood that the following description is not to limit the generality of the above description.
Example 1
To produce the solid dispersion, a solution was prepared by dispersing HP-50 (60g) in methylene chloride (1200 g) and then adding itraconazole (40 g) and stirring to form a pale brown solution. This solution was then spray dried to form a powder.
A portion (38.96 g) of this spray dried powder was then blended with sodium starch glycolate (14.87 g) and colloidal silicon dioxide (Aerosil 200)(0.75 g) in a mortar and pestle for 5 minutes. Magnesium stearate (1. 1 g) was added to the blend from the mortar and the mixture tumble blended until uniform.
This powder blend was then filled into size 0 gelatin capsules by hand. Each capsule was filled with 364 to 378 mg of powder, containing nominally 98 to 102 mg of itraconazole.
These capsules were tested in a standard USP type II dissolution bath (paddle method). A capsule was weighted with stainless steel wire and then dropped into 900 ml of dissolution media consisting of 0.05 M phosphate buffer solution adjusted to pH 6.0. Samples of this media were extracted at appropriate time intervals through a 10 micrometre filter and the content of itraconazole in the sample assayed using a HPLC method. Both the media in the dissolution bath and the extracted, filtered samples were cloudy in appearance. This test was also performed using 900 ml of hydrochloric acid acidic media (pH 1.2, 0.06 M HCI). In this case both the media and the samples were clear.
The measured amount of itraconazole present in the samples, as a percentage of the total possible amount, after various times in the test described above is presented in the table below. For comparison the results of the same tests performed on a marketed itraconazole capsule (Sporanox™) are also tabulated. Sporanox™ produced clear solutions in both media.
Figure imgf000016_0001
Example 2
To produce the solid dispersion, a solution was prepared by dispersing HP-50 (420 g) in methylene chloride (8400 g) and then adding itraconazole (280 g) and stirring to form a pale brown solution. This solution was then spray dried to form a powder.
A portion (292 g) of this spray dried powder was then blended with sodium starch glycolate (93.6 g) and colloidal silicon dioxide (Aerosil 200)(5.6 g) in a Collette mixer at high speed for 5 minutes. Magnesium stearate (8.8 g) was added to the blend from the Collette mixer and the mixture tumble blended until uniform.
This powder blend was then filled into size 0 gelatin capsules by hand. Each capsule was filled with 345 to 359 mg of powder, containing nominally 98 to 102 mg of itraconazole.
These test capsules were utilised in a pharmacokinetic study. 8 male volunteers were dosed with one 100 mg capsule after an overnight (10 hour) fast. The capsules were dosed with 240 ml water. At appropriate time intervals blood samples were taken from the subjects and the concentration of itraconazole in the plasma determined. The study was performed in a randomised 2 way crossover fashion with subjects receiving 100 mg itraconazole as a marketed capsule (Sporanox™) or as the test formulation described in example 2 above. The alternate dose was taken after a 2 week washout period.
A plot of the mean blood levels measured is as follows:
Mean hraconazole plasmas levels : CM4799
Figure imgf000018_0001
Time (hours)
The data was analysed and the following standard mean pharmacokinetic parameters were obtained.
Figure imgf000018_0002
It can be seen from these results that significantly higher plasma itraconazole levels are obtained from the formulation described in the example than the marketed capsule form under these conditions.
Indeed, it was expected that the itraconazole formulation of this invention would have a later Tmaχ (time to maximum blood concentration of active) than Sporanox™, due to the use of an enteric polymer, which should not have solublised until after passing through the stomach. This is in comparison to the water-soluble polymers used in Sporanox™ that would solublise in the stomach. However, it can be seen from the above data that the Tmax of the formulation of the present invention is at least similar to the Tmax of Sporanox™, if not shorter than it. Together with the greatly increased Cmax, this result was surprising.
Example 3
Test capsules from Example 2 containing 100 mg of itraconazole were also utilised in a pharmacokinetic study under fed conditions, primarily for comparison with the pharmacokinetic results of Example 2 to determine whether there was any food effect.
The study was again conducted as a single dose, crossover study in 8 health male adult subjects, but under fed conditions. The subjects commenced eating a standard high fat breakfast 20 minutes prior to dose administration, having fasted for at least 10 hours prior to that.
A two week washout period between administration of the dose for each of the two treatments was again used, and the comparative product was again two 100 mg itraconazole capsules marketed as Sporanox™.
At appropriate time intervals blood samples were taken from the subjects and the concentration of itraconazole in the plasma determined.
A plot of the mean blood levels from the fasted study of example 2 (Fasted Study CM4799) and the fed study of Example 3 (Fed Study CM6000) is as follows:
Mean Plasma Cncentrations of Itraconazole Containing Formulations of the Invention in the Fed and Fasted State
Figure imgf000020_0001
The data from the fed study of Example 3 was analysed and the following mean standard pharmacokinetic parameters were obtained:
Figure imgf000020_0002
It can be seen from these results that the example formulation produces plasma profiles considered bioequivalent in terms of AUC under fasting and fed conditions, due to the AUC under fed conditions being about 102% of the AUC under fasted conditions, which is well within the range of 80 to 120%. This is an indication that the total amount of drug absorbed over time is essentially equivalent under fed and fasted conditions.
Finally, it will be appreciated that there may be other variations and modifications to the compositions described herein that are also within the scope of the present invention.

Claims

Claims:
1. A pharmaceutical composition in the form of a solid dispersion of a practically insoluble drug and a polymer having acidic functional groups, wherein in vitro the composition forms a suspension.
2. A pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is such that, upon administration, a suspension is formed in vivo, the suspension being a homogeneous dispersion of particles.
3. A pharmaceutical composition according to claim 2, wherein the particles of the suspension, formed in vitro, are at least of a size where they in vitro diffract light such that the suspension presents as a cloudy suspension.
4. A pharmaceutical composition according to claim 2 or claim 3 wherein the particles of the suspension are of a size less than 10 micrometre but greater than 1 nm.
5. A pharmaceutical composition according to claim 2 or claim 3 wherein a portion of the particles is in microparticulate form and a portion of the particles is in nanoparticulate form.
6. A pharmaceutical composition according to claim 2 or claim 3 wherein at least a portion of the particles of the suspension are of a size less than 450 nm but greater than 1 nm, such that after passing the cloudy suspension through a 450 nm filter, the suspension remains cloudy.
7. A pharmaceutical composition according to any one of claims 1 to 6 wherein the suspension is present during in vitro dissolution testing at a pH in the range of 4.0 to 8.0.
8. A pharmaceutical composition according to any one of claims 1 to 6 wherein the suspension is present during in vitro dissolution testing at a pH in the range of 5.5 to 7.5.
9. A pharmaceutical composition according to claims 7 or 8 wherein the in vitro dissolution testing includes an acidic pre-treatment step.
10. A pharmaceutical composition according to claim 9 wherein the acidic pre-treatment step is suspension in a dissolution medium at a pH of about 1.2 for a period of about 20 minutes.
11. A pharmaceutical composition according to any one of claims 1 to 10 wherein the drug is an azole antifungal drug.
12. A pharmaceutical composition according to claim 11 wherein the azole antifungal drug is itraconazole.
13. A pharmaceutical composition according to claim 11 wherein the azole antifungal drug is saperconazole.
14. A pharmaceutical composition according to any one of claims 1 to 11 wherein the polymer is one or more of the group comprising hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose acetate succinate, alginate, carbomer, carboxymethyl cellulose, methacrylic acid copolymer, shellac, cellulose acetate phthalate, starch glycolate, polacrylin, cellulose acetate phthalate, methyl cellulose acetate phthalate, hydroxypropylcellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate and cellulose acetate trimellitate.
15. A pharmaceutical composition according to any one of claims 1 to 13 wherein the polymer is a hydroxypropyl methylcellulose phthalate.
16. A pharmaceutical composition according to any one of claims 1 to 15 wherein the ratio of drug to polymer is in the range of from 3:1 to 1 :20.
17. A pharmaceutical composition according to claim 16 wherein the ratio of drug to polymer is in the range of from 1 :1 to 1 :3.
18. A pharmaceutical composition according to any one of claims 1 to 17 wherein the solid dispersion is formed by spray drying techniques.
19. A pharmaceutical composition according to claim 18 wherein the polymer is dispersed within a solvent prior to dispersion of the drug, wherein the solvent is one or more of the group comprising methylene chloride, chloroform, ethanol, methanol, propan-2-ol, ethylacetate, acetone and water.
20. A pharmaceutical composition according to any one of claims 1 to 19 wherein the bioavailability of the drug in the pharmaceutical composition is at least twice the bioavailability of the drug per se.
21. A pharmaceutical composition according to any one of claims 1 to 20 wherein the composition has an AUC under fed conditions that is 80 to 125% of the composition's AUC under fasted conditions.
22. A pharmaceutical dosage form according to any of claims 1 to 21 wherein the composition has a reduced food effect compared to the drug per se.
23. A pharmaceutical dosage form containing a therapeutically effective amount of the pharmaceutical composition of any one of claims 1 to 22.
24. A pharmaceutical dosage form according to claim 23 including one or more excipients such as disintegrants, diluents, fillers, lubricants, glidants, colourants and flavours.
25. A pharmaceutical dosage form according to claim 23 or 24 wherein the dosage form is a capsule or a tablet.
26. A pharmaceutical composition in the form of a solid dispersion of an azole antifungal drug and a polymer having acidic functional groups, wherein in vitro the composition forms a suspension.
27. A pharmaceutical composition according to claim 26 wherein the suspension is present during in vitro dissolution testing at a pH in the range of 4.0 to 8.0.
28. A pharmaceutical composition according to claim 27 wherein the suspension is present during in vitro dissolution testing at a pH in the range of 5.5 to 7.5.
29. A pharmaceutical composition according to any one of claims 26 to 28 wherein the polymer is a hydroxypropyl methylcellulose phthalate.
30. A pharmaceutical composition according to any one of claims 26 to 29 wherein the drug is itraconazole.
31. A pharmaceutical composition according to any one of claims 26 to 30 wherein in vivo the composition provides a mean Cmaχ of at least 100 ng/ml, after administration of a 100 mg dose of the azole antifungal drug in the fasted state.
32. A pharmaceutical composition according to any one of claims 26 to 30 wherein in vivo the composition provides a mean Cmax of at least 150 to 250 ng/ml, after administration of a 100 mg dose of the azole antifungal drug in the fasted state.
33. A pharmaceutical composition according to any one of claims 26 to 32 wherein the composition provides a mean AUC of at least 800 ng.h/ml, after administration of a 100 mg dose of the azole antifungal drug in the fasted state.
34. A pharmaceutical composition according to any one of claims 26 to 32 wherein the composition provides a mean AUC of 1300 to 2300 ng.h/ml, after administration of a 100 mg dose of the azole antifungal drug in the fasted state.
35. A pharmaceutical composition according to any one of claims 26 to 34 wherein the composition has a reduced food effect compared to the drug per se.
36. A pharmaceutical composition including about 100 mg of an azole antifungal drug wherein in vivo the composition provides a mean Cmaχ of at least 100 ng/ml, after administration in the fasted state.
37. A pharmaceutical composition according to claim 36 wherein in vivo the composition provides a mean Cmax of at least 150 to 250 ng/ml, after administration of the azole antifungal drug in the fasted state.
38. A pharmaceutical composition including about 100 mg of an azole antifungal drug wherein the composition provides a mean AUC of at least 800 ng.h/ml, after administration in the fasted state.
39. A pharmaceutical composition according to claim 36 wherein the composition provides a mean AUC of 1300 to 2300 ng.h/ml, after administration of the azole antifungal drug in the fasted state.
40. A pharmaceutical composition according to any one of claims 34 to 37 wherein the azole antifungal drug is itraconazole.
41. A pharmaceutical composition in the form of a solid dispersion of a hydroxypropyl methylcellulose phthalate and a practically insoluble drug, wherein the composition forms a suspension in vitro in the pH range of 4.0 to 8.0 and provides acceptable absorption in the intestines.
42. A pharmaceutical composition according to claim 41 wherein the drug is itraconazole.
43. A pharmaceutical composition according to claim 41 or claim 42 wherein the suspension is present during in vitro dissolution testing at a pH in the range of 5.5 to 7.5.
44. A pharmaceutical composition according to any one of claims 36 to 43 wherein the composition has a reduced food effect compared to the drug per se.
45. A process for preparing a pharmaceutical composition of a practically insoluble drug, the process including the steps of:
(a) adding a polymer having acidic functional groups to a solvent to form a dispersion;
(b) adding the drug to the dispersion to form a suspension or solution; and
(c) spray drying the suspension or solution to form the pharmaceutical composition in the form of a solid dispersion.
46. A process according to claim 45 wherein step (a) is conducted so as not to dissolve the polymer acid.
47. A process according to claim 45 or claim 46 wherein the polymer is a hydroxypropyl methylcellulose phthalate.
48. A process according to any one of claims 45 to 47 wherein the solvent is methylene chloride.
49. A process according to any one of claims 45 to 48 wherein the drug is itraconazole.
50. A process according to any one of claims 45 to 49 wherein the solid dispersion is subsequently blended with one or more excipients to produce a powder for use in a pharmaceutical dosage form.
51. A process according to claim 50 wherein the blending occurs with grinding.
52. A process for preparing a pharmaceutical composition of a practically insoluble drug, the process including dispersing in a solvent the drug and a polymer having acidic functional groups, and spray drying the dispersion to form a solid dispersion.
53. A pharmaceutical composition of a practically insoluble drug, the composition having an AUC under fed conditions that is 80 to 125% of the composition's AUC under fasted conditions.
54. A pharmaceutical composition according to claim 53 wherein the composition is a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups.
55. A pharmaceutical composition according to claim 54 wherein the polymer is a hydroxypropyl methylcellulose phthalate.
56. A pharmaceutical composition according to claim 54 or claim 55 wherein in vitro the composition forms a suspension.
57. A pharmaceutical composition according to any one of claims 53 to 56 wherein the drug is an azole antifungal drug.
58. A pharmaceutical composition according to claim 57 wherein the drug is itraconazole.
59. A pharmaceutical composition according to claim 57 wherein the drug is saperconazole.
60. A pharmaceutical composition of a practically insoluble drug, wherein in vitro the composition forms a suspension.
61. A pharmaceutical composition according to claim 57 wherein the drug is an azole antifungal drug.
62. A pharmaceutical composition according to claim 58 wherein the drug is itraconazole.
63. A pharmaceutical composition according to claim 58 wherein the drug is saperconazole.
64. A pharmaceutical composition according to any one of claims 53 to 63 wherein the composition has a reduced food effect compared to the drug per se.
65. A process for preparing a pharmaceutical composition of a practically insoluble drug, the process including the steps of:
(a) adding the drug to a solvent to form a dispersion; (b) adding a polymer having acidic functional groups to the dispersion to form a suspension or solution; and
(c) spray drying the suspension or solution to form the pharmaceutical composition in the form of a solid dispersion.
PCT/AU2000/001592 1999-12-23 2000-12-22 Improved pharmaceutical compositions for poorly soluble drugs WO2001047492A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP00986890A EP1239831B1 (en) 1999-12-23 2000-12-22 Improved pharmaceutical compositions for poorly soluble drugs
JP2001548087A JP5159012B2 (en) 1999-12-23 2000-12-22 Improved pharmaceutical composition for poorly soluble drugs
ES00986890T ES2398643T3 (en) 1999-12-23 2000-12-22 Enhanced pharmaceutical compositions for sparingly soluble drugs
CA2396380A CA2396380C (en) 1999-12-23 2000-12-22 Improved pharmaceutical compositions for poorly soluble drugs
AU23318/01A AU2331801A (en) 1999-12-23 2000-12-22 Improved pharmaceutical compositions for poorly soluble drugs
US10/175,883 US20030086976A1 (en) 1999-12-23 2002-06-21 Pharmaceutical compositions for poorly soluble drugs
US10/461,503 US6881745B2 (en) 1999-12-23 2003-06-16 Pharmaceutical compositions for poorly soluble drugs
US11/763,578 US8771739B2 (en) 1999-12-23 2007-06-15 Pharmaceutical compositions for poorly soluble drugs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPQ4854A AUPQ485499A0 (en) 1999-12-23 1999-12-23 Improved pharmaceutical compositions for poorly soluble drugs
AUPQ4854 1999-12-23
AUPQ7450A AUPQ745000A0 (en) 2000-05-12 2000-05-12 Improved pharmaceutical compositions for poorly soluble drugs
AUPQ7450 2000-05-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/175,883 Continuation US20030086976A1 (en) 1999-12-23 2002-06-21 Pharmaceutical compositions for poorly soluble drugs

Publications (1)

Publication Number Publication Date
WO2001047492A1 true WO2001047492A1 (en) 2001-07-05

Family

ID=25646230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2000/001592 WO2001047492A1 (en) 1999-12-23 2000-12-22 Improved pharmaceutical compositions for poorly soluble drugs

Country Status (8)

Country Link
US (3) US20030086976A1 (en)
EP (2) EP2415462A1 (en)
JP (2) JP5159012B2 (en)
AU (2) AU782469B2 (en)
CA (1) CA2396380C (en)
ES (1) ES2398643T3 (en)
PT (1) PT1239831E (en)
WO (1) WO2001047492A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067904A1 (en) * 2001-02-27 2002-09-06 Astrazeneca Ab Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer
EP1296717A1 (en) * 2000-06-21 2003-04-02 Biochemie Gesellschaft M.B.H. Improvement of itraconazole bioavailability
US6737530B2 (en) 2000-05-24 2004-05-18 Astrazeneca Ab Process
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2009129301A2 (en) * 2008-04-15 2009-10-22 Schering Corporation Oral pharmaceutical compositions in a molecular solid dispersion
CN105722512A (en) * 2013-04-17 2016-06-29 梅恩医药国际有限公司 Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
US10561654B2 (en) 2011-11-23 2020-02-18 Array Biopharma Inc. Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US10568884B2 (en) 2009-08-28 2020-02-25 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
PT1239831E (en) * 1999-12-23 2013-01-23 Mayne Pharma International Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
JP2004534811A (en) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク Pharmaceutical composition comprising a polymer and drug assembly
CN1309370C (en) 2002-02-01 2007-04-11 辉瑞产品公司 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
CL2004001884A1 (en) * 2003-08-04 2005-06-03 Pfizer Prod Inc DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
JP2007308480A (en) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd Solid preparation containing enteric solid dispersion
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
RU2009102262A (en) * 2006-06-26 2010-08-10 Мьючуал Фармасьютикал Компани, Инк. (Us) COMPOSITIONS OF ACTIVE AGENT, WAYS OF THEIR OBTAINING AND WAYS OF APPLICATION
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
WO2008078922A1 (en) * 2006-12-22 2008-07-03 Yuhan Corporation Revaprazan-containing solid dispersion and process for the preparation thereof
US20100151035A1 (en) * 2007-03-13 2010-06-17 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
CL2009000902A1 (en) * 2008-04-15 2010-07-23 Merck Sharp & Dohme Composition comprising posaconazole dissolved or molecularly dispersed in a polymer derived from hydroxypropylcellulose; pharmaceutical formulation comprising the composition; a process for preparing the composition by fusioextrusion; and its use to treat a fungal infection.
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9650851B2 (en) 2012-06-18 2017-05-16 Schlumberger Technology Corporation Autonomous untethered well object
KR20150043296A (en) * 2012-06-21 2015-04-22 메인 파마 인터내셔널 프로프라이어터리 리미티드 Itraconazole compositions and dosage forms, and methods of using the same
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN104644557B (en) * 2013-11-22 2017-10-31 上海宣泰医药科技有限公司 PORPHYRIN IRON solid dispersions and preparation method thereof
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
JP2020503269A (en) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド Oral testosterone undecanoate therapy
JP2020506905A (en) * 2017-01-20 2020-03-05 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． (R) -N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl) -2-methyl-1- (1- (1- (2,2, 2-trifluoroethyl) piperidin-4-yl) ethyl) -1H-indole-3-carboxamide solid dispersion
AU2018321287A1 (en) 2017-08-20 2020-04-02 University Of Connecticut Azole analogues and methods of use thereof
US10702520B1 (en) 2019-01-29 2020-07-07 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
US11318107B2 (en) 2019-02-22 2022-05-03 Avior, Inc. Pharmaceutical active-containing film delivery device for oral transmucosal administration
WO2021037091A1 (en) * 2019-08-28 2021-03-04 深圳微芯生物科技股份有限公司 Chidamide pharmaceutical composition, preparation method therefor and application thereof
WO2021226166A1 (en) 2020-05-07 2021-11-11 Liang Guibai Prodrug of itraconazole and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
WO1998000113A1 (en) * 1996-06-28 1998-01-08 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
WO2000040220A1 (en) * 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
EP1027886A2 (en) * 1999-02-10 2000-08-16 Pfizer Products Inc. Pharmaceutical solid dispersions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02167219A (en) * 1988-12-20 1990-06-27 Fujisawa Pharmaceut Co Ltd Production of solid dispersion
JP3110794B2 (en) 1991-06-05 2000-11-20 ユーシービージャパン株式会社 Preparation containing 1,4-dihydropyridine derivative
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
ATE240734T1 (en) * 1995-07-26 2003-06-15 Kyowa Hakko Kogyo Kk PREPARATION OF XANTHINDERIVATES AS A SOLID DISPERSION
CN1165291C (en) * 1996-05-20 2004-09-08 詹森药业有限公司 Anti-fungus composition with improved biological utilization ratio
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
EP1039909B1 (en) * 1997-12-31 2002-10-09 Choongwae Pharma Corporation Method of production and composition of an oral preparation of itraconazole
KR100336090B1 (en) * 1998-06-27 2002-05-27 윤승원 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof
DE19843904A1 (en) * 1998-09-24 2000-03-30 Basf Ag Solid dosage form for prolonged slow release of e.g. drugs, plant treatment agents, or food or feed additives, containing copolymer of N-vinyl-lactam, methyl methacrylate and further monomer(s) as binder
PT1239831E (en) * 1999-12-23 2013-01-23 Mayne Pharma International Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
WO1998000113A1 (en) * 1996-06-28 1998-01-08 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
WO2000040220A1 (en) * 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
EP1027886A2 (en) * 1999-02-10 2000-08-16 Pfizer Products Inc. Pharmaceutical solid dispersions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAI T. ET AL.: "Oral absorption improvement of poorly soluble drug using solid dispersion technique", CHEM. PHARM. BULL., vol. 44, no. 3, 1996, pages 568 - 571, XP000582694 *
See also references of EP1239831A4 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737530B2 (en) 2000-05-24 2004-05-18 Astrazeneca Ab Process
EP1296717A1 (en) * 2000-06-21 2003-04-02 Biochemie Gesellschaft M.B.H. Improvement of itraconazole bioavailability
WO2002067904A1 (en) * 2001-02-27 2002-09-06 Astrazeneca Ab Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2009129301A2 (en) * 2008-04-15 2009-10-22 Schering Corporation Oral pharmaceutical compositions in a molecular solid dispersion
WO2009129301A3 (en) * 2008-04-15 2009-12-23 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
USRE49556E1 (en) 2009-08-28 2023-06-20 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
US10576080B2 (en) 2009-08-28 2020-03-03 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
US10568884B2 (en) 2009-08-28 2020-02-25 Array Biopharma Inc. Compounds and compositions as protein kinase inhibitors
US10561654B2 (en) 2011-11-23 2020-02-18 Array Biopharma Inc. Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US10328072B2 (en) 2013-04-17 2019-06-25 Hedgepath Pharmaceuticals, Inc. Treatment of lung cancer using hedgehog pathway inhibitors
US10363252B2 (en) 2013-04-17 2019-07-30 Hedgepath Pharmaceuticals, Inc. Treatment of prostate cancer using hedgehog pathway inhibitors
US9968600B2 (en) 2013-04-17 2018-05-15 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of non-cancerous proliferation disorders using hedgehog pathway inhibitors
US9962381B2 (en) 2013-04-17 2018-05-08 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of cancerous proliferation disorders using Hedgehog pathway inhibitors
EP2986296A4 (en) * 2013-04-17 2016-11-23 Mayne Pharma Int Pty Ltd Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN112043829A (en) * 2013-04-17 2020-12-08 梅恩医药国际有限公司 Treatment and prognostic monitoring of proliferative disorders using HEDGEHOG pathway inhibitors
CN105722512A (en) * 2013-04-17 2016-06-29 梅恩医药国际有限公司 Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors

Also Published As

Publication number Publication date
US6881745B2 (en) 2005-04-19
US20080260835A1 (en) 2008-10-23
EP1239831B1 (en) 2012-10-31
EP1239831A1 (en) 2002-09-18
AU782469B2 (en) 2005-08-04
CA2396380C (en) 2015-04-21
AU2331801A (en) 2001-07-09
CA2396380A1 (en) 2001-07-05
JP5159012B2 (en) 2013-03-06
ES2398643T3 (en) 2013-03-20
JP2003518483A (en) 2003-06-10
AU7252900A (en) 2001-06-28
EP2415462A1 (en) 2012-02-08
US20030225104A1 (en) 2003-12-04
US20030086976A1 (en) 2003-05-08
US8771739B2 (en) 2014-07-08
JP2012236837A (en) 2012-12-06
PT1239831E (en) 2013-01-23
EP1239831A4 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
US8771739B2 (en) Pharmaceutical compositions for poorly soluble drugs
US20200060976A1 (en) Formulations of enzalutamide
AU2021277731B2 (en) Improved formulations of deferasirox and methods of making the same
KR100348585B1 (en) Pharmaceutical preparations with darfenacin
BG106764A (en) Pharmaceutical compositions providing enhanced drug concentrations
AU2007338359B2 (en) Pharmaceutical formulation comprising neurokinin antagonist
JP2003505509A (en) β-carboline pharmaceutical composition
JP2011516613A (en) An oral pharmaceutical composition in a solid dispersion, preferably comprising posaconazole and HPMCAS
EP4079295A1 (en) Composition having improved solubility and bioavailability of olaparib
CA2393737A1 (en) Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption
EP1154762B1 (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
KR102300335B1 (en) Oral Formulation of Aprepitant
US20050038111A1 (en) Pharmaceutical formulation comprising bicalutamide
WO2022115052A1 (en) Improved wet granulation processes for apixaban comprising formulations
TW202435886A (en) Milvexian pharmaceutical compositions
EA041538B1 (en) SUSPENSION BASED ON LEVOCLOPERASTIN FENDIZOATE WITH INCREASED SOLUBILITY AND RESUSPENDIABILITY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000986890

Country of ref document: EP

Ref document number: 10175883

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2001 548087

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2396380

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000986890

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642